Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE PHOSPHATE vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Radical cure of relapsing malaria caused by Plasmodium vivax or P. ovale,Prevention of relapse in malaria due to P. vivax or P. ovale,Off-label: Terminal prophylaxis of malaria (after leaving endemic area) to prevent relapse,Combination therapy for treatment of uncomplicated malaria (with clindamycin or other agents)
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Primaquine is extensively metabolized in the liver, primarily via CYP2C8 and CYP2D6. Major metabolites include carboxyprimaquine and other oxidative products.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
Approximately 70% bound to plasma proteins (primarily albumin).
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
2.5-3.5 L/kg; extensive distribution into tissues including liver, lungs, and erythrocytes.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: approximately 75-80% (first-pass metabolism reduces systemic availability; food decreases rate but not extent).
Oral: 80-90%.
No specific guidelines; use with caution in renal impairment. For severe renal impairment (Cr Cl <30 m L/min), consider alternative therapy due to lack of data.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor for adverse effects; dose adjustment not well defined, but consider reducing dose to 15 mg (base) daily and monitoring G6PD status.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
Children: For radical cure of P. vivax or P. ovale: 0.5 mg/kg (base) orally once daily for 14 days (maximum 30 mg). For prophylaxis: 0.5 mg/kg (base) orally once daily (maximum 30 mg) starting 1 day before travel, daily during travel, and 7 days after leaving endemic area. Must test for G6PD deficiency before use.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
No specific dose adjustments; use with caution due to age-related decline in hepatic and renal function. Monitor for hemolytic anemia and gastrointestinal effects. Consider lower starting dose (15 mg base daily) and adjust based on tolerability.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
Primaquine phosphate can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency must be ruled out before starting treatment. Severe hemolysis may occur and can lead to death.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Hemolytic anemia in G6PD-deficient patients: Screen for G6PD deficiency prior to use and avoid in such patients unless benefit outweighs risk,Methemoglobinemia: Can occur, especially in patients with NADH-methemoglobin reductase deficiency or other predisposing conditions,Hematologic toxicity: Monitor blood counts; caution in patients with anemia or other blood disorders,Hepatic impairment: Use with caution; may need dose adjustment,Psychiatric effects: Rarely associated with anxiety, confusion, or psychosis
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
G6PD deficiency (absolute contraindication due to risk of hemolytic anemia),Known hypersensitivity to primaquine or other 8-aminoquinolines,Concurrent use with other hemolytic agents or drugs causing methemoglobinemia,Lupus erythematosus (relative contraindication; may exacerbate),Rheumatoid arthritis (relative contraindication; may exacerbate)
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Grapefruit juice may increase plasma concentrations of primaquine, raising risk of toxicity. Take with food to reduce gastrointestinal irritation. No other significant food interactions known.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk of hemolytic anemia in G6PD-deficient fetuses; use only if clearly needed.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Excreted into breast milk in small amounts. M/P ratio not established. Use caution; avoid in G6PD-deficient infants. Consider risk of hemolytic anemia.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may affect efficacy; however, standard dosing is typically used with careful monitoring.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Primaquine is the only 8-aminoquinoline used for radical cure of Plasmodium vivax and P. ovale hypnozoites. Screen for G6PD deficiency before initiation to prevent hemolytic anemia. Administer with food to reduce gastrointestinal upset. Watch for methemoglobinemia; discontinue if cyanosis or oxygen saturation drops. Avoid in pregnancy and lactation unless benefit outweighs risk.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take with food or milk to prevent stomach upset.,Complete the full course even if you feel better.,Report dark urine, yellowing of skin/eyes, or unusual tiredness immediately.,Avoid grapefruit juice as it may increase side effects.,Do not use during pregnancy or breastfeeding without consulting your doctor.,Keep out of reach of children and store at room temperature.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE PHOSPHATE vs ARALEN, answered by our medical review team.
PRIMAQUINE PHOSPHATE is a Antimalarial that works by Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE PHOSPHATE and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE PHOSPHATE is: Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE PHOSPHATE and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE PHOSPHATE is classified as Category D/X. FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk . ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.